Skip to main content
. 2023 Nov 22;6(4):805–827. doi: 10.20517/cdr.2023.77

Figure 13.

Figure 13

(A) Schematic illustration of synergistic PTT and CT using supramolecular polypeptide nanomedicine (BPC/DOX-ICG); (B) The P-gp expression levels in MCF-7/ADR cells with different treatments; (C) Changes of tumor volume in tumor-bearing mice with different formulations (**P < 0.01, ***P < 0.001). This figure is quoted with permission from Ding et al.[174]. DOX: Doxorubicin; ICG: indocyanine green; MDR: multidrug resistance; NIR: near-infrared; PPNC: pyridinium-terminal-modified polypeptide.